Anna Sala-Puigdollers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/379236/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Vitrectomized vs non-vitrectomized eyes in DEX implant treatment for DMO—Is there any difference? the VITDEX study. Eye, 2023, 37, 280-284.	1.1	12
2	Optical Coherence Tomography Angiography in Type 1 Diabetes Mellitus—Report 2: Diabetic Kidney Disease. Journal of Clinical Medicine, 2022, 11, 197.	1.0	5
3	Uveitic macular edema response to intravitreal dexamethasone implant is independent of optical coherence tomography findings. International Ophthalmology, 2021, 41, 787-796.	0.6	0
4	GRAding of functional and anatomical response to DExamethasone implant in patients with Diabetic Macular Edema: GRADE-DME Study. Scientific Reports, 2021, 11, 4738.	1.6	3
5	Systemic contribution of inflammatory mediators to the severity of diabetic and uveitic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 2695-2705.	1.0	4
6	Optical Coherence Tomography Angiography in Type 1 Diabetes Mellitus. Report 4: Glycated Haemoglobin. Diagnostics, 2021, 11, 1537.	1.3	6
7	Long-Term Intravitreal Dexamethasone Implant Outcomes in Uveitis. Ocular Immunology and Inflammation, 2020, 28, 228-237.	1.0	8
8	Disorganization of retinal inner layers as a biomarker in patients with diabetic macular oedema treated with dexamethasone implant. Acta Ophthalmologica, 2020, 98, e217-e223.	0.6	75
9	Differential response to intravitreal dexamethasone implant in naÃ ⁻ ve and previously treated diabetic macular edema eyes. BMC Ophthalmology, 2020, 20, 443.	0.6	10
10	Optical Coherence Tomography Angiography in Type 1 Diabetes Mellitus. Report 1: Diabetic Retinopathy. Translational Vision Science and Technology, 2020, 9, 34.	1.1	22
11	Baseline predictors for visual acuity loss during observation in diabetic macular oedema with good baseline visual acuity. Acta Ophthalmologica, 2020, 98, e801-e806.	0.6	11
12	Aqueous Humour Cytokine Changes with Intravitreal Dexamethasone Implant Injection for Diabetic Macular Edema. Ocular Immunology and Inflammation, 2019, 27, 1203-1210.	1.0	7
13	Multimodal retinal imaging of familial amyloid polyneuropathy. Ophthalmic Genetics, 2019, 40, 407-420.	0.5	13
14	Causative Pathogens of Endophthalmitis after Intravitreal Anti-VEGF Injection: An International Multicenter Study. Ophthalmologica, 2019, 241, 211-219.	1.0	12
15	Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study. Acta Diabetologica, 2019, 56, 777-784.	1.2	27
16	Anatomic Response to Intravitreal Dexamethasone Implant and Baseline Aqueous Humor Cytokine Levels in Diabetic Macular Edema. , 2019, 60, 1336.		23
17	Evaluation of microvascular changes in the perifoveal vascular network using optical coherence tomography angiography (OCTA) in type I diabetes mellitus: a large scale prospective trial. BMC Medical Imaging, 2019, 19, 91.	1.4	12
18	Long-term probability of intraocular pressure elevation with the intravitreal dexamethasone implant in the real-world. PLoS ONE, 2019, 14, e0209997.	1.1	23

#	Article	IF	CITATIONS
19	OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant. Ophthalmology, 2018, 125, 267-275.	2.5	188
20	Repeatability and reproducibility of retinal and choroidal thickness measurements in Diabetic Macular Edema using Swept-source Optical Coherence Tomography. PLoS ONE, 2018, 13, e0200819.	1.1	14
21	Peripheral blood metabolic and inflammatory factors as biomarkers to ocular findings in diabetic macular edema. PLoS ONE, 2017, 12, e0173865.	1.1	25
22	Interleukinâ€⊋2 serum levels are elevated in active scleritis. Acta Ophthalmologica, 2016, 94, e395-9.	0.6	13
23	InÂVivo Imaging of Cortical Vitreous Using 1050-nm Swept-Source Deep Range Imaging Optical Coherence Tomography. American Journal of Ophthalmology, 2014, 157, 397-404.e2.	1.7	45